Study:
Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin`s Lymphoma
Rationale:
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer
cells and either kill them or deliver cancer-killing substances to them without harming
normal cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining
chemotherapy with monoclonal antibody therapy and radiation therapy may kill more cancer
cells.
Purpose:
Phase II trial to study the effectiveness of combination chemotherapy plus
rituximab and radiation therapy in treating patients who have stage I or stage II
non-Hodgkin`s lymphoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy |
Phase 2 |
Verified by
Southwest Oncology Group
January, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00005089
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Thomas P. Miller, MD., Study Chair